COVID Update: Masks are still required in health care settings, even if you’re fully vaccinated. Also, Scripps does not provide COVID-19 tests for asymptomatic patients. See FAQs.

Investigational Drug for Advanced or Metastatic Solid Tumor Cancers

Trial ID:
IRB-21-7826
Darren Sigal, M.D.
This study will test the safety and effectiveness of OBI-999 (investigational study drug), given once every three weeks via intravenous infusion (IV) in patients with locally advanced or metastatic solid tumor cancer.

Inclusion Criteria

Patients must:
  • Be 18 years of age or older
  • Be ambulatory and able to carry out work of a light or sedentary nature.
  • Have a tissue specimen from a prior biopsy to be submitted for Globo-H analysis

Exclusion Criteria

Patients must not:
  • Be pregnant or nursing
  • Be taking immunosuppressive therapies (i.e._cyclosporine, rapamycin, tacrolimus, cyclophosphamide, or methotrexate) or require daily systemic steroids of >10 mg/day
  • Have a history of solid organ transplant
  • Have known untreated central nervous system disease

Additional Info

  • All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion).
  • Study treatment is given once every three weeks by intravenous infusion (IV).
  • Search for NCT04084366 on https://clinicaltrials.gov/ for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org